Relevium’s Bioganix® Now Live on Amazon.co.uk
September 20 2018 - 9:20AM
MONTREAL, Sept. 20, 2018 (GLOBE NEWSWIRE) --
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and
Frankfurt: “6BX”) (the “Company”
or
“Relevium”) is pleased to
announce that the Bioganix® brand is now available for purchase in
the United Kingdom (“UK”) on the Amazon.co.uk platform.
As announced on April 5, 2018, the Company has
begun selling its Bioganix® nutraceutical products in the UK. The
Company experienced some delays during the onboarding process but
is now fully operational with some of the current highest volume
sellers in Amazon.com, which include: Pure Forskolin, White Kidney
Bean Extract, BioPro 50 and Turmeric Curcumin. The product line
will expand as inventory becomes available and will commence
preparing to expand to other European countries such as Germany,
France, Italy and Spain.
Aurelio Useche, CEO of Relevium stated:
“Now that we have established a presence in the European market, it
is anticipated that further regional rollouts will be less time
consuming.” Mr. Useche continued: “We believe that the European
market will be an exceptional opportunity for all Relevium brands
be it for Bioganix® or others. The Operations Team is seeing a
significant opportunity and we have high expectations for our core
nutraceutical line, as well as, CBD infused and formulated
products”
About Relevium Technologies
Relevium is a publicly-traded company that
operates in the $3.7 trillion-dollar worldwide wellness industry.
Relevium is focused on the development, acquisition, marketing and
sale of consumer products that are derived from cannabis and
industrial hemp and other ingredients that are generally accepted
as safe. The Company uses cannabinoids and ingredients that have
achieved GRAS status (generally accepted as safe) to create brands
that are sold via wholesale channels, retail channels and online
distribution.
Relevium markets its products as dietary
supplements, nutraceuticals, sports nutrition and cosmeceuticals.
The Company plans on unveiling a complete line of dietary
supplements for consumers derived from Cannabis Sativa and Cannabis
Indica. The Company’s initial focus will be on creating a full
spectrum extract rich in CBD (cannabidiol) which will be marketed
and sold throughout Europe and North America. Relevium is also
focused on developing a complete line of supplements,
nutraceuticals, sports nutrition and cosmeceuticals. Relevium’s
products and brands such as Bioganix® have achieved
market penetration and now sold at some of the world’s largest
retailers such as Walmart.com.
Cautionary Note Regarding
Forward-Looking Statements
This release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws. All statements in this news
release, other than statements of historical facts, including
statements regarding future estimates, plans, objectives,
assumptions or expectations of future performance, including the
timing and completion of the proposed acquisitions, are
forward-looking statements and contain forward-looking information.
Generally, forward- looking statements and information can be
identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", "would" or "occur". Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, including the assumptions that the Company
will be able to apply for and ultimately obtain an ACMPR licence,
the proposed business of Biocannabix will develop as anticipated,
that the Company will raise sufficient funds to develop the
Biocannabix business, and that the Company will obtain all
requisite regulatory approvals. These forward-looking statements
are subject to known and unknown risks, uncertainties and other
factors that may cause the actual results, level of activity,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward-looking
statements or forward-looking information. Important factors that
may cause actual results to vary, include, without limitation, the
risk that the proposed business developments may not occur as
planned; the timing and receipt of requisite approvals and failure
to raise sufficient funds. Although management of the Company has
attempted to identify important factors that could cause actual
results to differ materially from those contained in
forward-looking statements or forward-looking information, there
may be other factors that cause results not to be as anticipated,
estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward- looking statements and forward-looking information.
Readers are cautioned that reliance on such information may not be
appropriate for other purposes. The Company does not undertake to
update any forward-looking statement, forward-looking information
or financial outlook that are incorporated by reference herein,
except in accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Relevium Technologies (CE) (USOTC:RLLVF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Relevium Technologies (CE) (USOTC:RLLVF)
Historical Stock Chart
From Sep 2023 to Sep 2024